Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase II Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

Telavant announced the initiation of the TAHOE study, a Phase II clinical trial of RVT-3101 for the treatment of moderate to severely active Crohn’s disease, with the first patient dosed.